Joint Formulary & PAD

Fluocinolone acetonide - Diabetic macular oedema

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Fluocinolone acetonide
Indication :
Diabetic macular oedema
Group Name :
Keywords :
DMO, Retinal disorder
Brand Names Include :
Iluvien
Important Information :
Ophthalmology specialists only. In patients who have failed to respond to prior treatments.
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
3

Other Indications

Below are listed other indications that Fluocinolone acetonide is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Diabetic macular oedema.

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves fluocinolone acetonide intravitreal implant as a treatment option in line with the recommendations made in NICE TA953, for treating diabetic macular oedema.

 

Fluocinolone acetonide for this indication will be considered as RED on the traffic light system (treatment should be initiated and continued by specialist clinicians).

 

Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed a Diabetic Macular Oedema (DMO) treatment pathway attached below for information.